Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.

Qian LiYifan WangWeijuan JiaWeiye DengGuangdi LiJiewen ChenBetty Y S KimWen Jiang Jieqiong Liu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Together, these results demonstrate a dose-dependent synergism between anti-angiogenic therapy and immune checkpoint blockade, thus providing important insights into the optimal strategies for combining immunotherapy with molecular-targeted agents.

Keyphrases

low dose
high dose
stem cells
single molecule
induced apoptosis